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Abstract
Introduction: We conducted a study to analyze how infection by hepatitis C virus (HCV) may influence the
immunological serum pattern of patients with Sjögren syndrome (SS).
Methods: Since 1994, we have tested serum HCV-IgG antibodies in 783 patients with SS diagnosed according to
the 1993 European classification criteria. The immunological profile at diagnosis was compared according to the
presence or absence of HCV.
Results: Of the 783 patients with SS, 105 (13.4 %) tested positive for HCV-IgG antibodies (88 females, 17 males,
mean age at SS diagnosis: 62.9 years). Multivariate analysis showed that patients with SS-HCV had a higher mean
age and a higher frequency of low C3/C4 levels, cryoglobulins, and hematological neoplasia compared with
patients without HCV. The frequency of anti-La antibodies compared with anti-Ro antibodies was higher in patients
with SS-HCV (17 % vs. 15 %) and lower in patients without HCV infection (30 % vs. 43 %). The frequency of
concomitant detection of the three main cryoglobulin-related markers (cryoglobulins, rheumatoid factor activity,
and C4 consumption) was threefold higher in patients with SS-HCV compared with patients without HCV. SS-HCV
patients with genotype 1b showed the highest frequencies of immunological abnormalities related to cryoglobulins
and the lowest frequencies of anti-Ro/La antibodies.
Conclusions: We found HCV infection in 13 % of a large series of Spanish patients with SS. The HCV-driven
autoimmune response was characterized by a lower frequency of anti-Ro/La antibodies, an abnormal
predominance of anti-La among anti-Ro antibodies, and a higher frequency of cryoglobulinemic-related
immunological markers in comparison with patients without HCV infection. This immunological pattern may
contribute to the poor outcomes found in patients with SS-HCV.
Introduction
Sjögren syndrome (SS) is a systemic autoimmune disease
that mainly affects the exocrine glands. This leads to
dryness of the main mucosal surfaces, such as the
mouth, eyes, nose, pharynx, larynx, and vagina [1]. The
disease overwhelmingly affects middle-aged women but
may also affect children, men, and older patients. The
clinical spectrum of SS extends from dryness affecting
the main mucosal surfaces to systemic involvement
(extraglandular manifestations). SS may be a serious
disease with excess mortality, which is related mainly to
systemic involvement and hematological cancer [2].
In the etiopathogenesis of SS, a specific combination
of individual genetic predisposition (intrinsic factors)
and environmental agents (extrinsic factors) may be cen-
tral to the development of the disease [3]. Viruses have
always been considered one of the main exogenous cul-
prits implicated in the etiopathogenesis of SS, and the
hepatitis C virus (HCV) is a principal candidate [4]. In
the last 15 years, several experimental, virological, and
clinical studies have shown a close association between
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HCV and SS [5], suggesting that there may be shared
immune-mediated etiopathogenic mechanisms. It sounds
reasonable to investigate the role of the human ribonu-
cleoproteins among these mechanisms. Human La protein
is an essential factor in the biology of both coding and
non-coding RNAs, is one of the principal autoantigens
implicated in the etiopathogenesis of SS, and has been
shown to play a key role in the initiation of HCV transla-
tion [6]. It could be hypothesized that patients carrying
antibodies against Ro/La ribonucleoproteins are protected
against chronic HCV infection.
The study of a large cohort of SS patients who were
tested for HCV infection may help characterize the im-
munological profile of SS according to the presence or ab-
sence of HCV and reveal possible relationships between
the main virological HCV features and the immunological
expression of a systemic autoimmune disease character-
ized by an autoimmune response against human ribonu-
cleoproteins, some of which have also been implicated in
the translation and replication of HCV.
Methods
Since 1994, we have tested 783 consecutive patients with
primary SS diagnosed according to the 1993 European
classification criteria for serum HCV-IgG antibodies [7];
patients with concomitant systemic autoimmune diseases
other than SS were excluded. Fulfillment of the 2002
American-European criteria [8] and the preliminary 2012
American College of Radiology (ACR) criteria [9] was
retrospectively evaluated: 470 (60 %) fulfilled the 2002 cri-
teria, and 499 (64 %) the preliminary 2012 criteria (29 pa-
tients fulfilled the 2012 criteria but not the 2002 criteria
since they had positive rheumatoid factor (RF) and antinu-
clear antibodies (ANA) titers above 320, but with negative
Ro/La antibodies/salivary gland biopsy).
HCV infection was defined as a positive serological
result for serum HCV antibodies in at least two determi-
nations. Anti-HCV antibodies were detected by second-
generation enzyme-linked immunosorbent assay (ELISA)
between 1994 and 1998 and third-generation ELISA
since 1998; all patients who tested positive for the
second-generation ELISA were re-tested with the third-
generation test. Serum HCV-RNA was detected by poly-
merase chain reaction, viral load by real-time polymer-
ase chain reaction (COBAS TaqMan HCV Test, Roche
Diagnostics, Manheim, Germany), and HCV genotype by
restriction fragment-length polymorphism of the 5′ non-
coding region of the HCV genome, as previously
described [10]. Virological studies (serum HCV-RNA de-
tection, viral load, and genotype) were carried out ac-
cording to clinical reasons and were not available in all
patients. SS patients who tested HCV antibody-positive
but HCV-RNA-negative were considered as having a
past HCV infection that was resolved, whereas those
who tested positive for serum HCV-RNA were consid-
ered currently chronic HCV-infected.
A protocol form was used to retrospectively record the
main characteristics of patients, including sex, age at
diagnosis of SS (defined as the age when the patient ful-
filled the current classification criteria), diagnostic tests
for SS (ocular tests, salivary scintigraphy, salivary gland
biopsy defined according to the recommendations of the
European Community Study Group) [7], virological fea-
tures (serum HCV-IgG, serum HCV-RNA, maximum
viral load in the absence of anti-HCV therapies, HCV
genotype), and adverse outcomes (neoplasia, death) until
the last visit or death. The study was approved by the
Ethics Committee of the Hospital Clinic of Barcelona
(Spain), and the study design conformed to current
Spanish ethical standards. Owing to the retrospective,
observational, and anonymous nature of the study, in-
formed patient consent was not required.
Immunological studies
Immunological tests were made by using commercial
techniques standardly used in the Spanish public health-
care system, including ANA (indirect immunofluo-
rescence using mouse liver and Hep-2 cells as substrate),
precipitating antibodies to extractable nuclear antigens
(Ro/SS-A, La/SS-B, U1-snRNP, and Sm; enzyme-linked
immunoassay), and RF (nephelometry). Complement was
measured by determination of C3 and C4 levels by nephe-
lometry (BNII nephelometer; Dade Behring, Manburg,
Germany). Serum cryoglobulins were measured after cen-
trifugation. Blood samples were obtained and maintained
at 37 °C for 30 min before separation. Serum was prepared
by centrifuging at 37 °C for 10 min at 2500 revolutions
per minute. Fresh centrifuged serum was incubated at
4 °C for 7 days after collection and examined for cryopre-
cipitation. Cryoglobulins were further analyzed by immu-
nofixation when more than 5 % of cryoprecipitate was
available. Serum monoclonal immunoglobulins were ana-
lyzed by immunofixation electrophoresis on agarose gels
with specific antisera to IgG, IgM, IgA, and κ and λ chains
at diagnosis and every year during the follow-up. Immu-
nofixation was performed by using a Helena Immu-
nofixation Agarose Kit (Helena Laboratories, Beaumont,
TX, USA) in accordance with the instructions of the
manufacturer.
Statistical analysis
Descriptive data are presented as mean and standard devi-
ation for continuous variables and as number and percent-
age for categorical variables. Qualitative differences were
analyzed by using the chi-squared and Fisher’s exact tests.
When several independent variables appeared to be sta-
tistically significant in the univariate analysis, logistic
regression was made in a multivariate analysis to rule out
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possible confounding variables. To compare quantitative
parameters, the Student’s t test was used in large samples of
similar variance, and the non-parametric Mann–Whitney
U test was used for small samples. A P value of less
than 0.05 indicated statistical significance. The ana-
lysis was carried out by using the 18.0 SPSS program
(SPSS, Chicago, IL, USA).
Results
Prevalence of HCV infection
Of the 783 patients with SS, 105 (13.4 %) tested positive
for HCV-IgG antibodies (88 females and 17 males, with a
mean age at SS diagnosis of 62.9 years). The prevalence
varied according to the SS criteria fulfilled: 8 % (38/470) in
patients fulfilling the 2002 criteria, 10 % (51/499) in pa-
tients fulfilling the 2012 ACR criteria, and 19 % (54/284)
in patients fulfilling only the 1993 criteria; the highest per-
centage was found in the 29 patients who fulfilled the
2012 criteria but not the 2002 criteria (13 patients were
HCV-positive, 45 %).
Comparison between HCV-IgG-positive and -negative
patients
Table 1 summarizes the main features of patients accord-
ing to the presence or absence of serum HCV-IgG anti-
bodies. In the univariate analysis, patients with SS-HCV
Table 1 Main SS-related features of patients according to the presence or absence of serum HCV-IgG antibodies
Negative HCV-IgG Positive HCV-IgG Bilateral P value
N = 678 N = 105
Mean age, years 56.36 ± 14.83 62.93 ± 11.86 <0.001*
Sex, male 45 (7 %) 17 (16 %) 0.003
Dry mouth 661 (98 %) 103 (98 %) 1
Dry eye 661 (98 %) 104 (99 %) 0.493
Altered ocular tests 559/609 (92 %) 82/88 (93 %) 0.834
Altered parotid scintigraphy 486/554 (88 %) 45/54 (83 %) 0.389
Positive salivary gland biopsy 198/309 (64 %) 21/30 (70 %) 0.556
Criteria SS
- 1993 only 230 (34 %) 54 (51 %) <0.001
- 2002 432 (64 %) 38 (26 %)
- ACR only 16 (2 %) 13 (12 %)
Antinuclear antibody+ 568/676 (84 %) 79/104 (76 %) 0.05
Rheumatoid factor+ 267/663 (40 %) 57/102 (56 %) 0.004
Anti-Ro/SS-A+ 292/676 (43 %) 16/103 (15 %) <0.001*
Anti-La/SS-B+ 200/676 (30 %) 17/103 (17 %) 0.006
Monoclonal gammopathy 85/492 (17 %) 35/75 (47 %) <0.001
Type of monoclonal band
- mIgA 9 (11 %) 1 (3 %) 0.047
- mIgG 47 (55 %) 13 (37 %)
- mIgM 18 (21 %) 15 (43 %)
- Free chains 11 (13 %) 6 (17 %)
Type of monoclonal light chain
- Kappa:lambda 50:35 19:16 0.65
Cryoglobulin+ 41/626 (7 %) 63/104 (61 %) <0.001*
Low C3 levels, <0.82 g/l 70/660 (11 %) 37/103 (36 %) <0.001*
Low C4 levels, <0.11 g/l 45/660 (7 %) 49/103 (48 %) <0.001*
Hematological neoplasia 26 (4 %) 9 (9 %) 0.04*
Neoplasia 54 (8 %) 21 (20 %) <0.001*
Death 52 (8 %) 35 (33 %) <0.001
*Statistically significant in the multivariate model.
SS Sjögren syndrome, HCV hepatitis C virus, IgG immunoglobulin G, ACR American College of Rheumatology, SS-A Sjögren syndrome A antigen, SS-B Sjögren
syndrome B antigen, mIg circulating monoclonal immunoglobulin, C3 complement component 3, C4 complement component 4Bold numbers: statistically-
significant differences in the univariate analysis (p<0.05)
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had a higher mean age (63 vs. 56 years, P < 0.001), were
more frequently male (16 % vs.7 %, P=0.003), less fre-
quently fulfilled the 2002 SS criteria (26 % vs. 64 %, P <
0.001), and had a higher frequency of RF (56 % vs. 40 %,
P=0.004), low C3 levels (36 % vs. 11 %, P < 0.001), low C4
levels (48 % vs. 7 %, P < 0.001), serum monoclonal gam-
mopathy (47 % vs. 17 %, P < 0.001), and cryoglobulinemia
(61 % vs. 7 %, P < 0.001); a lower frequency of ANA (76 %
vs. 84 %, P=0.05), anti-Ro (15 % vs. 43 %, P < 0.001), and
anti-La (17 % vs. 30 %, P < 0.001); and a higher frequency
of adverse outcomes, including hematological neoplasia
(9 % vs. 4 %, P=0.04), neoplasia (20 % vs. 8 %, P < 0.001),
and death (33 % vs. 8 %, P < 0.001) compared with pa-
tients without HCV infection; age, anti-Ro antibodies, low
C3 levels, low C4 levels, cryoglobulins, and hematological
neoplasia were significant independent variables in the
multivariate model.
Characteristics of SS patients with past HCV infection
Serum HCV-RNA determination was available in 77 (73 %)
of the 105 SS patients who tested positive for HCV-IgG
antibodies. Seven (9 %) of the 77 patients were negative for
serum HCV-RNA and were considered as having a resolved
HCV infection. All seven patients were female, with a mean
age of 66 years, and all had the same autoantibody profile
(positive for ANA but negative for anti-Ro and anti-La anti-
bodies). No statistically significant differences existed be-
tween patients with past HCV infection and those with
chronic HCV infection (data not shown).
Association between HCV genotypes and SS features
Genotype determination was available in 44 (42 %) pa-
tients with SS: 30 (70 %) patients had genotype 1b, eight
(19 %) genotype 1a, and the remaining five (11 %) non-1
genotypes, including genotypes 2 (n=1), 3 (n=2), and 4
(n=2); in one sample, HCV was not genotypable by the
molecular assay. Table 2 summarizes the main features
of SS patients according to the main HCV genotypes.
Patients with genotype 1b had the highest frequencies of
immunological abnormalities related to cryoglobulins
(cryoglobulinemia, monoclonal gammopathy, and RF)
and the lowest frequencies of anti-Ro/La antibodies
compared with patients with other genotypes.
Influence of HCV on the SS-related autoantibody profile
Table 3 shows the distribution of the main SS-related
immunological markers (ANA, RF, anti-Ro and anti-La
antibodies, cryoglobulins, low C3/C4 levels) according to
the presence or absence of HCV infection. A total of
232 patients with SS had positive ANA or RF (or both)
in the absence of anti-Ro/La antibodies; SS patients
without HCV had a higher frequency of isolated ANA
and a lower frequency of isolated RF compared with pa-
tients with SS-HCV (65 % vs. 43 % and 4 % vs. 18 %,
respectively, P <0.001). Anti-Ro/La antibodies were posi-
tive in 335 patients (190 had both autoantibodies, 118 only
anti-Ro, and 27 only anti-La). Patients with SS-HCV had a
lower frequency of isolated anti-Ro antibodies and a
higher frequency of isolated anti-La antibodies compared
with SS patients without HCV infection (36 % vs. 19 %
and 24 % vs. 7 %, respectively, P=0.014). Patients with SS-
HCV had a higher frequency of combined cryoglobulin-
related markers (cryoglobulins, RF, and low C4) and a
lower frequency of isolated cryoglobulins compared with
SS patients without HCV infection (47 % vs. 18 %
and 15 % vs. 34 %, respectively, P=0.019).
Comparison according to the presence of antibodies
against the La autoantigen
Patients with SS-HCV had a higher frequency of anti-La
antibodies than of anti-Ro antibodies (17 % vs. 15 %).
Comparison of the main characteristics of patients with
SS-HCV according to the presence or absence of anti-La
antibodies showed no significant differences (data not
shown). We also compared the main features of the SS pa-
tients carrying anti-La antibodies according to the pres-
ence or absence of HCV infection (Table 4). SS-HCV
patients carrying La autoantibodies had a higher mean age
(59.6 vs. 51 years, P=0.03), were more frequently male
(23 % vs. 4 %, P=0.003), and had a higher frequency of low
C3 levels (53 % vs. 10 %, P < 0.001), low C4 levels (65 % vs.
7 %, P < 0.001), serum monoclonal gammopathy (54 % vs.
20 %, P=0.01), and cryoglobulinemia (53 % vs. 10 %, P <
0.001); a predominance of lambda monoclonal gammopa-
thies (71 % vs. 30 %, P=0.041); a lower frequency of anti-Ro
(71 % vs. 89 %, P=0.044) and anti-Ro (15 % vs. 43 %, P <
0.001); and a higher frequency of death (41 % vs. 8 %,
P=0.001) compared with HCV-negative SS patients carry-
ing anti-La antibodies.
Discussion
HCV was identified as the main cause of the so-called
non-A non-B viral hepatitis 25 years ago [11]. Later, a
close link between chronic HCV infection and the
development of autoimmune processes was reported,
principally with two systemic autoimmune diseases: cryo-
globulinemic vasculitis and SS [12]. A large number of
studies have linked SS with HCV, including the common
finding of focal sialadenitis in patients with HCV [13], the
development of an SS-like exocrinopathy in transgenic
mice carrying the HCV envelope genes [14], the infection
and replication of HCV in epithelial cells from salivary
glands of patients with SS or chronic sialadenitis [15], and
the discovery of the key role of the La protein in facilitat-
ing the internal initiation of translation and replication of
HCV-RNA [16]. These findings support a specific role for
HCV in the etiopathogenesis of a subgroup of patients
with diagnosed “primary” SS.
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We found HCV infection in 13 % of a large series of Span-
ish patients who fulfilled the 1993 classification criteria for
SS (8 % in patients fulfilling the more restrictive 2002 cri-
teria). Various studies have analyzed the prevalence of
chronic HCV infection in patients with primary SS, and
most have found a higher prevalence than in the general
population, although the results vary according to the geo-
graphic area. Studies from southern Europe describe a
prevalence ranging from 10 % to 20 % (14 % using ELISA-3
and 5 % to 19 % using RIBA-2) [5]. In contrast, studies from
Scandinavia and the USA have found no association be-
tween SS and HCV (prevalence of less than 1 %) and this is
possibly due to the lower prevalence of HCV infection in
these countries compared with the Mediterranean area [17].
We tested the largest SS population from a single center for
HCV infection and found a prevalence 10-fold higher than
that found in the general Spanish population [18], although
it is possible that there may be a potential referral bias.
Demographically, SS-HCV was characterized by a com-
paratively reduced female-to-male ratio (5:1 vs. 14:1 in pa-
tients with primary SS) and an older age at SS diagnosis.
The clinical phenotype of SS-HCV was indistinguishable
from that of primary SS, and there were no significant dif-
ferences in the prevalence of sicca features and the corre-
sponding diagnostic tests. The sialotropism of HCV [4]
may explain the close association with SS, including the
results of salivary gland biopsies in patients with HCV.
Experimental studies have reported that the envelope pro-
teins of HCV may recruit lymphocytes in the salivary
glands, leading to the formation of lymphocytic infiltrates,
as occurs in primary SS (focal sialadenitis) [13–15]. De Vita
et al. [19] first detected HCV in human salivary glands,
Table 2 Main SS-related features of patients according to the HCV genotypes (1a, 1b, and non-1 genotypes)
Genotype 1a Genotype 1b Non-1 genotypes Bilateral P value
N = 8 N = 30 N = 5
Mean age, years 62.62 ± 12.62 64.93 ± 9.81 46.00 ± 8.15 0.002
Sex, male 0 (0 %) 8 (27 %) 2 (40 %) 0.182
Dry mouth 8 (100 %) 30 (100 %) 5 (100 %) 1.000
Dry eye 8 (100 %) 30 (100 %) 5 (100 %) 1.000
Altered ocular tests 5/6 (83 %) 23/24 (96 %) 4/5 (80 %) 0.381
Altered parotid scintigraphy 4/5 (80 %) 14/17 (82 %) 2/3 (67 %) 0.822
Positive salivary gland biopsy 5/5 (100 %) 3/5 (60 %) 0/2 (0 %) 0.037
Criteria SS
- 1993 only 3 (37 %) 20 (67 %) 2 (40 %) 0.175
- 2002 5 (63 %) 7 (23 %) 3 (60 %)
- ACR only 0 (0 %) 3 (10 %) 0 (0 %)
Antinuclear antibody+ 6 (75 %) 26 (87 %) 4 (80 %) 0.709
Rheumatoid factor+ 3 (37 %) 16/29 (55 %) 1 (20 %) 0.284
Anti-Ro/SS-A+ 2 (25 %) 3 (10 %) 2 (40 %) 0.185
Anti-La/SS-B+ 1 (12 %) 5 (17 %) 2 (40 %) 0.410
Monoclonal gammopathy 3 (37 %) 13/26 (50 %) 0/1 (0 %) 0.535
Type of monoclonal band
- mIgA/mIgG/mIgM/free chains 0/0/2/1 1/6/5/1 0/0/0/0 0.34
- Kappa:lambda light chains 1:2 6:7 0 1.000
Cryoglobulin+ 4 (50 %) 20/29 (69 %) 0 (0 %) 0.014
Low C3 levels, <0.82 g/l 3 (37 %) 12 (40 %) 3 (60 %) 0.677
Low C4 levels, <0.11 g/l 4 (50 %) 13 (43 %) 2 (40 %) 0.926
Hematological neoplasia 1 (12 %) 3 (10 %) 1 (20 %) 0.809
Neoplasia 1 (12 %) 6 (20 %) 1 (20 %) 0.886
Death 4 (50 %) 9 (30 %) 0 (0 %) 0.161
Viral load > 5,000,000 2 (25 %) 11/28 (39 %) 0/5 (0 %) 0.095
Max viral load (log) 6.36 ± 0.39 6.13 ± 0.55 5.96 ± 0.38 0.350
SS Sjögren syndrome, HCV hepatitis C virus, IgG immunoglobulin G, ACR American College of Radiology, SS-A Sjögren syndrome A antigen, SS-B Sjögren syndrome
B antigen, mIg circulating monoclonal immunoglobulin, C3 complement component 3, C4 complement component 4Bold numbers: statistically-significant
differences in the univariate analysis (p<0.05)
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and two additional studies [20, 21] have demonstrated the
capability of the HCV to infect and replicate in the salivary
gland tissue of HCV patients with sicca syndrome/SS. The
reasons for the specific predilection of HCV for infecting
exocrine gland tissue are unknown.
The autoantibody profile of patients with HCV-related
SS is characterized by a higher frequency of RF and a
lower frequency of Ro/La antibodies [5]. This immu-
nological pattern influences the fulfillment of the new
classification criteria proposed after the 1993 criteria,
making fulfillment of the 2002 criteria (positivity for Ro/
La is mandatory in the absence of a positive salivary gland
result) more difficult than fulfillment of the 2012 criteria
(these criteria allow the inclusion of patients with positive
ANA/RF even in the absence of Ro/La antibodies). As the
results of this study show, the prevalence of HCV infec-
tion in patients with SS may vary widely according to the
set of criteria used to classify patients with SS.
In patients with SS, the HCV-driven autoimmune re-
sponse is dominated principally by the presence of
mixed cryoglobulins, reported in nearly two thirds of pa-
tients with SS-HCV (a ninefold higher prevalence with
respect to patients with primary SS). Cryoglobulins play
a predominant role in the global immunological pattern
of these patients and is closely associated with positive
RF, monoclonal gammopathy, and low C4 levels, whose
frequencies (either isolated or in combination) were
higher than those observed in patients without HCV. In
addition, we found significant differences in the serum
monoclonal expression (frequency and heterogeneity) of
patients with SS according to the presence or absence of
HCV infection. The prevalence of circulating mIgs in
patients with SS-HCV was threefold higher than in pa-
tients without HCV, and mIgMκ, which was closely re-
lated to mixed cryoglobulinemia, was the most common
type of circulating mIg, whereas in patients without
HCV, mIgGk was the predominant circulating monoclo-
nal band. We also found that SS-HCV patients with
monoclonal gammopathy had a more restrictive monoclo-
nal expression (overwhelmingly limited to either mIgMk
or mIgG) compared with patients without HCV, who pre-
sented all types of monoclonal heavy and light chains.
This suggests that HCV may play an important role in the
clonal selection of specific B cells [22].
The lymphotropism of HCV links the virus not only to
the synthesis of cryoglobulins but also to the development
of lymphoma [23], and we found a higher frequency of
hematological neoplasia in patients with SS-HCV com-
pared with those without HCV. Lymphomagenesis in
patients with HCV might be initiated by chronic stimula-
tion of polyclonal B cells by the virus [24] and the
compartmentalization of HCV quasispecies in blood
mononuclear cells [25], with the posterior development of
specific B-cell clonal expansions and pro-carcinogenic
mutations [26, 27], which are similar to the etiopathogenic
mechanisms of lymphoma development reported in pri-
mary SS [24, 28, 29]. Primary SS is the systemic auto-
immune disease with the highest risk of lymphoma
development [30]: we found that the combination of HCV
and SS doubled the risk reported in patients with SS
alone. Both SS and chronic HCV infection are character-
ized by underlying B-cell hyperactivity which predisposes
Table 3 Combination of the main SS-related immunological profiles (ANA/RF, Ro/La, and cryoglobulinemic-related markers) according
to the presence or absence of serum HCV-IgG antibodies
ANA/RF combination Negative HCV-IgG Positive HCV-IgG Bilateral P value
N = 306 N = 74
ANA and RF 94 (31 %) 29 (39 %) <0.001
Isolated ANA 200 (65 %) 32 (43 %)
Isolated RF 12 (4 %) 13 (18 %)
Ro/La combination Negative HCV-IgG Positive HCV-IgG Bilateral P value
N = 314 N = 21
Anti-Ro and anti-La antibodies 178 (57 %) 12 (57 %) 0.014
Isolated anti-Ro antibodies 114 (36 %) 4 (19 %)
Isolated anti-La antibodies 22 (7 %) 5 (24 %)
Cryoglobulinemic-related markers combination Negative HCV-IgG Positive HCV-IgG Bilateral P value
N = 38 N = 60
Cryoglobulins+RF+low C4 7 (18 %) 28 (47 %) 0.019
Cryoglobulins+RF 12 (32 %) 13 (22 %)
Cryoglobulins+low C4 6 (16 %) 10 (17 %)
Isolated cryoglobulins 13 (34 %) 9 (15 %)
SS Sjögren syndrome, ANA antinuclear antibodies, RF rheumatoid factor, HCV hepatitis C virus, IgG immunoglobulin G, C4 complement component 4
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to monoclonal B-cell selection [31]; therefore, SS-HCV
may present one of the highest risks of overt B-cell lymph-
oma of all systemic autoimmune diseases.
Human La protein is known to be an essential host
factor for the translation and replication of HCV RNA
[32]. Translation of HCV is an essential step of viral rep-
lication and is mediated by an internal ribosome entry
site, and the ribonucleoprotein La is a potent regulator
for the enhancement of HCV replication [33]. We tested
the hypothesis that patients carrying anti-La antibodies
could be protected against chronic HCV infection. Un-
fortunately, the results suggest that serum anti-La anti-
bodies do not play a significant protective role against
chronification of HCV infection in patients with SS.
None of the seven SS patients who had a resolved HCV
infection (positive HCV-IgG with negative HCV-RNA)
carried anti-La antibodies. In addition, we found no sig-
nificant differences in the epidemiological, clinical, and
immunological profile of La-positive patients according
to the presence or absence of HCV infection.
We found an abnormal Ro/La immunological pattern
according to the presence or absence of HCV infection.
First, we found that the prevalence of anti-Ro/La anti-
bodies was significantly reduced in patients with SS-HCV
compared with patients without HCV. Second, we found
more patients with SS-HCV were carrying La autoanti-
bodies than those carrying anti-Ro autoantibodies, and
this is in clear opposition to results found in SS patients
without HCV. Third, we found that nearly one quarter of
Ro/La+ SS-HCV patients carried isolated anti-La anti-
bodies, an immunological pattern rarely reported in pri-
mary SS (<5 %). These findings suggest that, in patients
with SS, the autoimmune response against the human La
protein is significantly altered by the concomitant pres-
ence of HCV infection, an abnormal response probably re-
lated to the use of human ribonucleoproteins by the virus.
Table 4 Main SS-related features of the 17 SS-HCV patients with anti-La antibodies in comparison with the 200 SS patients with
anti-La antibodies without HCV infection
Anti-La+ SS patients with HCV infection Anti-La+ SS patients with no HCV infection Bilateral P value
N = 17 N = 200
Mean age, years 59.59 ± 11.87 51.04 ± 15.77 0.03
Sex, male 4 (23 %) 8 (4 %) 0.009*
Dry mouth 16 (94 %) 197 (99 %) 0.280
Dry eye 17 (100 %) 196 (98 %) 1.000
Altered ocular tests 15/16 (94 %) 176/187 (94 %) 1.000
Altered parotid scintigraphy 9/10 (90 %) 151/165 (91 %) 0.602
Positive salivary gland biopsy 3/3 (100 %) 55/61 (90 %) 1.000
Antinuclear antibody+ 14 (82 %) 170/199 (85 %) 0.723
Rheumatoid factor+ 13/17 (77 %) 112/191 (59 %) 0.199
Anti-Ro/SS-A+ 12 (71 %) 178 (89 %) 0.044
Monoclonal gammopathy 7/13 (54 %) 33/166 (20 %) 0.01
Type of monoclonal band
- mIgA 0 (0 %) 3 (9 %) 0.87
- mIgG 4 (57 %) 17 (52 %)
- mIgM 2 (29 %) 9 (27 %)
- Free chains 1 (14 %) 4 (12 %)
Type of monoclonal light chain
- Kappa:lambda 2:5 23:10 0.041
Cryoglobulin+ 9 (53 %) 19/188 (10 %) <0.001
Low C3 levels, <0.82 g/l 9 (53 %) 22/196 (11 %) <0.001*
Low C4 levels, <0.11 g/l 11 (65 %) 14/196 (7 %) <0.001*
Hematological neoplasia 0 (0 %) 7 (3.5 %) 1.000
Neoplasia 4 (23.5 %) 17 (8.5 %) 0.067
Death 7 (41 %) 16 (8 %) 0.001
*Statistically significant in the multivariate model
SS Sjögren syndrome, HCV hepatitis C virus, SS-A Sjögren syndrome A antigen, mIg circulating monoclonal immunoglobulin, C3 complement component 3,
C4 complement component 4Bold numbers: statistically-significant differences in the univariate analysis (p<0.05)
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The study has some limitations related to the small
number of patients included in some comparisons, such
as the low number of patients with resolved HCV infec-
tion (only 7) or the low percentage of HCV patients with
available viral genotyping in whom a salivary gland bi-
opsy was carried out (only 12 out of 43 patients). In
these comparisons, the statistically significant results
should be taken with caution and require confirmation
by studies including a large number of patients.
Conclusions
In summary, we found HCV infection in 13 % of a large
series of Spanish patients with SS. The HCV-driven auto-
immune response in patients with SS-HCV is characterized
by a lower frequency of autoantibodies against Ro and La
human ribonucleoproteins, an abnormal predominant pres-
ence of anti-La among anti-Ro antibodies, and a higher fre-
quency of cryoglobulinemic-related immunological markers
(including positive RF) in comparison with SS patients
without HCV. This immunological pattern influences the
fulfillment of the SS classification criteria and may be re-
lated to the increased prevalence of hematological neopla-
sia that we found in patients with SS-HCV.
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